Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial to investigate ARV-110 in patients with metastatic castration-resistant prostate cancer

Trial Profile

A clinical trial to investigate ARV-110 in patients with metastatic castration-resistant prostate cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2019

At a glance

  • Drugs ARV-110 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Jan 2019 According to an Arvinas media release, the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug application (IND) for ARV-110 and enrollment in this trial is expected to begin in the first quarter of 2019.
    • 06 Nov 2017 New trial record
    • 02 Nov 2017 According to an Arvinas media release, this trial is expected to begin in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top